SSA
AIM

Schonfeld Strategic Advisors’s AIM ImmunoTech AIM Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-108
Closed -$11K – 3357
2022
Q1 		$11K Sell
108
-3
-3% -$258 ﹤0.01% 2421
2021
Q4 		$10K Sell
111
-1
-0.9% -$155 ﹤0.01% 2043
2021
Q3 		$23K Sell
112
-119
-52% -$24K ﹤0.01% 2046
2021
Q2 		$49K Sell
231
-154
-40% -$33K ﹤0.01% 1875
2021
Q1 		$88K Buy
+385
New +$86.9K ﹤0.01% 1680

Other funds holding AIM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Schonfeld Strategic Advisors's AIM Position: Q2 2022 in Review

Schonfeld Strategic Advisors sold out of AIM ImmunoTech (AIM) in Q2 2022, closing a stake of 108 shares — an estimated $11K sold.

Schonfeld Strategic Advisors first reported a position in AIM in Q1 2021 and held it in 5 quarters. The position peaked at $88K in Q1 2021. 36 funds tracked by Wall St. Rank hold AIM as of Q2 2022.

  • Schonfeld Strategic Advisors reported no remaining AIM ImmunoTech position as of Q2 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 108 AIM ImmunoTech shares in Q2 2022, an estimated $11K.
  • Schonfeld Strategic Advisors first reported a position in AIM ImmunoTech in Q1 2021 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's AIM ImmunoTech position peaked at $88K in Q1 2021.
  • 36 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.